Last updated on March 2018

PrEP and Consumptions

Brief description of study

HIV pre-exposure prophylaxis (PrEP) with Truvada, a combination of two antiretrovirals (tenofovir & emtricitabine) is a prevention strategy for HIV-negative people at high risk of acquiring HIV. PrEP has thus been integrated as a new tool to significantly reduce the risk of HIV infection, especially among men who have sex with men (MSM). Since its introduction, an increase in sexually transmitted infections (STIs) has been observed, particularly in relation to the use of psychoactive substances in a sexual context (Chemsex).

In this context, the description and evaluation of these practices seem necessary, as well as the impact on the risk of addiction and mental health.

Detailed Study Description

Interventional, multi-center pilot study, including all subjects aged 18 years or older presenting in consultation for a PrEP renewal.

The newsletter and a self-questionnaire will be systematically given in the waiting room to any PrEP consultant to evaluate the consumption of psychoactive substances (ASSIST questionnaire) and to identify anxio-depressive disorders (HAD questionnaire - Hospital Anxiety and Depression). scale). After consent, the answers will be discussed with the doctor during the consultation for appropriate care, including a referral to a psychiatrist and / or addictologist if necessary.

The duration of the inclusions will be 6 months and the number of patients to include is 250.

Clinical Study Identifier: NCT03449771

Contact Investigators or Research Sites near you

Start Over

Dominique Bastide, MD

Hospital of Al s
Alès, France
  Connect »

Jean-Marc Jacquet, MD

Uh Montpellier
Montpellier, France
  Connect »

Béatrice Broche, MD

Nîmes, France
  Connect »

Jean-Marc Mauboussin, MD

Nîmes, France
  Connect »

Milagos Ferreyra, MD

Hospital of Perpignan
Perpignan, France
  Connect »